AU765776B2 - Spontaneously dispersible N-benzoyl staurosporine compositions - Google Patents

Spontaneously dispersible N-benzoyl staurosporine compositions Download PDF

Info

Publication number
AU765776B2
AU765776B2 AU31542/00A AU3154200A AU765776B2 AU 765776 B2 AU765776 B2 AU 765776B2 AU 31542/00 A AU31542/00 A AU 31542/00A AU 3154200 A AU3154200 A AU 3154200A AU 765776 B2 AU765776 B2 AU 765776B2
Authority
AU
Australia
Prior art keywords
surfactant
composition
benzoylstaurosporine
pharmaceutical composition
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU31542/00A
Other languages
English (en)
Other versions
AU3154200A (en
Inventor
Barbara Haberlin
Graham Paul Matthews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU765776(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU3154200A publication Critical patent/AU3154200A/en
Application granted granted Critical
Publication of AU765776B2 publication Critical patent/AU765776B2/en
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU31542/00A 1999-02-16 2000-02-14 Spontaneously dispersible N-benzoyl staurosporine compositions Expired AU765776B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
GB9903547 1999-02-16
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (2)

Publication Number Publication Date
AU3154200A AU3154200A (en) 2000-09-04
AU765776B2 true AU765776B2 (en) 2003-10-02

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31542/00A Expired AU765776B2 (en) 1999-02-16 2000-02-14 Spontaneously dispersible N-benzoyl staurosporine compositions

Country Status (34)

Country Link
US (3) US20020061873A1 (enExample)
EP (1) EP1152750B1 (enExample)
JP (2) JP5057610B2 (enExample)
KR (2) KR20080064914A (enExample)
CN (1) CN100367930C (enExample)
AR (2) AR022589A1 (enExample)
AT (1) ATE430554T1 (enExample)
AU (1) AU765776B2 (enExample)
BR (1) BRPI0008228B8 (enExample)
CA (1) CA2362277C (enExample)
CL (1) CL2009001682A1 (enExample)
CZ (1) CZ303979B6 (enExample)
DE (1) DE60042151D1 (enExample)
DK (1) DK1152750T3 (enExample)
EC (1) ECSP083351A (enExample)
ES (1) ES2326783T3 (enExample)
GB (1) GB9903547D0 (enExample)
HK (1) HK1045807B (enExample)
HU (1) HUP0105364A3 (enExample)
ID (1) ID30504A (enExample)
IL (3) IL144512A0 (enExample)
MY (1) MY128362A (enExample)
NO (1) NO331232B1 (enExample)
NZ (1) NZ513529A (enExample)
PE (1) PE20001499A1 (enExample)
PL (1) PL198330B1 (enExample)
PT (1) PT1152750E (enExample)
RU (1) RU2266121C2 (enExample)
SI (1) SI1152750T1 (enExample)
SK (1) SK286967B6 (enExample)
TR (1) TR200102385T2 (enExample)
TW (1) TWI240636B (enExample)
WO (1) WO2000048571A1 (enExample)
ZA (1) ZA200106677B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
CA2444867C (en) 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US7973031B2 (en) 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
PT2054040E (pt) * 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
CN102781425B (zh) * 2009-12-22 2014-08-13 利奥制药有限公司 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
ES2981002T3 (es) 2015-12-09 2024-10-04 Avecho Biotechnology Ltd Formulación farmacéutica
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
AU2017381395A1 (en) 2016-12-21 2019-06-20 Phosphagenics Limited Process
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657164A1 (en) * 1993-12-11 1995-06-14 Ciba-Geigy Ag Pharmaceutical compositions containing staurosphorine derivatives
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (enExample) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
CA2108266C (en) 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ES2168271T3 (es) * 1992-09-25 2002-06-16 Novartis Ag Composiciones farmaceuticas que contienen ciclosporinas.
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
US5707648A (en) 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
EP0763041A1 (en) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
IL115742A (en) * 1994-10-26 2000-06-01 Novartis Ag Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
WO1998013032A1 (en) 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
KR20040004416A (ko) * 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
NZ502569A (en) 1997-07-29 2002-05-31 Upjohn Co Self-emulsifying formulation for lipophilic compounds comprising a mixture of diglyceride and monoglyceride in a ratio of 9:1 to 6:4
BR9810866B1 (pt) 1997-07-29 2010-07-13 composição farmacêutica em uma forma de formulação auto-emulsificante para compostos lipofìlicos.
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657164A1 (en) * 1993-12-11 1995-06-14 Ciba-Geigy Ag Pharmaceutical compositions containing staurosphorine derivatives
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
US5726164A (en) * 1995-03-21 1998-03-10 Novartis Corporation Nanosuspensions for intravenous administration

Also Published As

Publication number Publication date
NO331232B1 (no) 2011-11-07
KR20010093281A (ko) 2001-10-27
US8575147B2 (en) 2013-11-05
PL350556A1 (en) 2002-12-16
SK286967B6 (sk) 2009-08-06
ZA200106677B (en) 2003-01-14
HUP0105364A2 (hu) 2002-05-29
HUP0105364A3 (en) 2003-02-28
HK1045807B (zh) 2008-12-05
CN100367930C (zh) 2008-02-13
CN1339963A (zh) 2002-03-13
US20020061873A1 (en) 2002-05-23
NO20013964L (no) 2001-10-15
US8722664B2 (en) 2014-05-13
ID30504A (id) 2001-12-13
IL192666A0 (en) 2009-02-11
BR0008228A (pt) 2001-10-30
AR022589A1 (es) 2002-09-04
AR082579A2 (es) 2012-12-19
PL198330B1 (pl) 2008-06-30
GB9903547D0 (en) 1999-04-07
EP1152750B1 (en) 2009-05-06
HK1045807A1 (zh) 2002-12-13
KR20080064914A (ko) 2008-07-09
CZ20012931A3 (cs) 2001-11-14
EP1152750A1 (en) 2001-11-14
ECSP083351A (es) 2008-08-29
WO2000048571A1 (en) 2000-08-24
IL144512A0 (en) 2002-05-23
TWI240636B (en) 2005-10-01
PT1152750E (pt) 2009-08-07
PE20001499A1 (es) 2001-01-12
CL2009001682A1 (es) 2010-07-23
JP2002537242A (ja) 2002-11-05
MY128362A (en) 2007-01-31
US20140056974A1 (en) 2014-02-27
RU2266121C2 (ru) 2005-12-20
KR100880859B1 (ko) 2009-01-30
SI1152750T1 (sl) 2009-10-31
US20080070897A1 (en) 2008-03-20
AU3154200A (en) 2000-09-04
BRPI0008228B8 (pt) 2021-05-25
NO20013964D0 (no) 2001-08-15
BRPI0008228B1 (pt) 2016-08-23
JP2012111763A (ja) 2012-06-14
DE60042151D1 (de) 2009-06-18
NZ513529A (en) 2003-10-31
DK1152750T3 (da) 2009-08-24
JP5057610B2 (ja) 2012-10-24
CA2362277A1 (en) 2000-08-24
ES2326783T3 (es) 2009-10-20
SK11722001A3 (sk) 2001-12-03
ATE430554T1 (de) 2009-05-15
CZ303979B6 (cs) 2013-07-31
CA2362277C (en) 2010-03-30
IL144512A (en) 2011-03-31
TR200102385T2 (tr) 2002-09-23

Similar Documents

Publication Publication Date Title
US8575147B2 (en) Spontaneously dispersible N-benzoyl staurosporine compositions
AU765935B2 (en) Substantially oil-free cyclosporin compositions
AU755134B2 (en) Microemulsion preconcentrates containing a piperidine substance P antagonist
JP2014503520A (ja) 医薬組成物
US20080254113A1 (en) Microemulsion Formulations Comprising Particular Substance P Antagonists
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
HK1035137B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist
ZA200006597B (en) Microemulsion preconcentrates containing a piperidine substance p antagonist.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: RYDAPT MIDOSTAURIN

Filing date: 20180517

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: RYDAPT MIDOSTAURIN

Filing date: 20180517

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: RYDAPT MIDOSTAURIN

Filing date: 20180517

Extension date: 20250214